Literature DB >> 26453627

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.

J Stuart Elborn1, Scott C Bell2, Susan L Madge3, Pierre-Regis Burgel4, Carlo Castellani5, Steven Conway6, Karleen De Rijcke7, Birgit Dembski8, Pavel Drevinek9, Harry G M Heijerman10, J Alistair Innes11, Anders Lindblad12, Bruce Marshall13, Hanne V Olesen14, Andreas L Reimann15, Ampara Solé16, Laura Viviani17, Thomas O F Wagner18, Tobias Welte19, Francesco Blasi20.   

Abstract

The improved survival in people with cystic fibrosis has led to an increasing number of patients reaching adulthood. This trend is likely to be maintained over the next decades, suggesting a need to increase the number of centres with expertise in the management of adult patients with cystic fibrosis. These centres should be capable of delivering multidisciplinary care addressing the complexity of the disease, in addition to addressing the psychological burden on patients and their families. Further issues that require attention are organ transplantation and end of life management.Lung disease in adults with cystic fibrosis drives most of the clinical care requirements, and major life-threatening complications, such as respiratory infection, respiratory failure, pneumothorax and haemoptysis, and the management of lung transplantation require expertise from trained respiratory physicians. The taskforce therefore strongly reccommends that medical leadership in multidisciplinary adult teams should be attributed to a respiratory physician adequately trained in cystic fibrosis management.The task force suggests the implementation of a core curriculum for trainees in adult respiratory medicine and the selection and accreditation of training centres that deliver postgraduate training to the standards of the HERMES programme.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2015        PMID: 26453627     DOI: 10.1183/13993003.00592-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

1.  Cystic Fibrosis: The Dawn of a New Therapeutic Era.

Authors:  Sonya L Heltshe; Jonathan Cogen; Kathleen J Ramos; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2017-04-15       Impact factor: 21.405

2.  Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis.

Authors:  Pierre-Régis Burgel; Gil Bellis; J Stuart Elborn
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

3.  Biological Variation of Chloride and Sodium in Sweat Obtained by Pilocarpine Iontophoresis in Adults: How Sure are You About Sweat Test Results?

Authors:  Philippe Willems; Steven Weekx; Anissa Meskal; Sofie Schouwers
Journal:  Lung       Date:  2017-02-27       Impact factor: 2.584

4.  Propofol directly binds to and inhibits TLR7.

Authors:  Sophia Koutsogiannaki; Weiming Bu; Wiriya Maisat; Mariel Manzor; Zhikuan Zhang; Umeharu Ohto; Roderic G Eckenhoff; Koichi Yuki
Journal:  FASEB J       Date:  2022-08       Impact factor: 5.834

Review 5.  [Evidence-based treatment of cystic fibrosis].

Authors:  F C Ringshausen; T Hellmuth; A-M Dittrich
Journal:  Internist (Berl)       Date:  2020-12       Impact factor: 0.743

Review 6.  Cystic Fibrosis.

Authors:  Susanne Naehrig; Cho-Ming Chao; Lutz Naehrlich
Journal:  Dtsch Arztebl Int       Date:  2017-08-21       Impact factor: 5.594

Review 7.  [Cystic fibrosis : A new disease pattern in adult medicine].

Authors:  D Staab; C Schwarz
Journal:  Internist (Berl)       Date:  2018-11       Impact factor: 0.743

Review 8.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

Review 9.  Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series.

Authors:  Christina M Mingora; Patrick A Flume
Journal:  Chest       Date:  2021-06-17       Impact factor: 10.262

10.  A retrospective 'real-world' cohort study of azole therapeutic drug monitoring and evolution of antifungal resistance in cystic fibrosis.

Authors:  M Di Paolo; L Hewitt; E Nwanko; M Ni; A Vidal-Diaz; M C Fisher; D Armstrong-James; A Shah
Journal:  JAC Antimicrob Resist       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.